MedTrace Logo

Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease

NCT02471196 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 308

Last updated 2018-02-15

No results posted yet for this study

Summary

This study evaluates the effect of ORM-12741 on agitation/aggression symptoms in Alzheimer's disease. Two thirds of the patients will receive ORM-12741 and one third will receive placebo.

Conditions

Interventions

DRUG

ORM-12741

ORM-12741 low dose twice a day

DRUG

ORM-12741

ORM-12741 high dose twice a day

DRUG

Placebo

Placebo twice a day

Sponsors & Collaborators

  • Janssen Pharmaceuticals

    collaborator INDUSTRY

  • Orion Corporation, Orion Pharma

    lead INDUSTRY

Principal Investigators

  • Juha Rinne, Prof · Clinical Research Services Turku - CRST Oy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-14
Primary Completion
2017-10-09
Completion
2017-12-04

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02471196 on ClinicalTrials.gov